{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:45:50Z","timestamp":1786373150948,"version":"build-2736575974"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.2215\/cjn.09941014","type":"journal-article","created":{"date-parts":[[2015,7,31]],"date-time":"2015-07-31T22:29:27Z","timestamp":1438381767000},"page":"1749-1756","source":"Crossref","is-referenced-by-count":24,"title":["Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan"],"prefix":"10.2215","volume":"10","author":[{"given":"Laura R.","family":"Harskamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy E.","family":"Boertien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van Oeveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin E.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"van Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20230601","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1053\/j.ajkd.2003.10.002","article-title":"Cystic and inherited kidney diseases.","volume":"42","author":"Rizk","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R2-9-20230601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000112495","article-title":"Autosomal dominant polycystic kidney disease: Recent advances in pathogenesis and treatment.","volume":"108","author":"Chang","year":"2008","journal-title":"Nephron, Physiol"},{"key":"R3-9-20230601","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.2215\/CJN.00790209","article-title":"A case for water in the treatment of polycystic kidney disease.","volume":"4","author":"Torres","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R4-9-20230601","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"R5-9-20230601","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"R6-9-20230601","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1161\/HYPERTENSIONAHA.108.113860","article-title":"Epidermal growth factor receptor signaling in the kidney: Key roles in physiology and disease.","volume":"52","author":"Melenhorst","year":"2008","journal-title":"Hypertension"},{"key":"R7-9-20230601","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of disease: Autosomal dominant and recessive polycystic kidney diseases.","volume":"2","author":"Torres","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"R8-9-20230601","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/ki.1992.184","article-title":"In vitro formation and expansion of cysts derived from human renal cortex epithelial cells.","volume":"41","author":"Neufeld","year":"1992","journal-title":"Kidney Int"},{"key":"R9-9-20230601","first-page":"386","article-title":"Renal cysts in transgenic mice expressing transforming growth factor-alpha.","volume":"124","author":"Lowden","year":"1994","journal-title":"J Lab Clin Med"},{"key":"R10-9-20230601","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/ki.2013.285","article-title":"Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease.","volume":"84","author":"Boertien","year":"2013","journal-title":"Kidney Int"},{"key":"R11-9-20230601","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"R12-9-20230601","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0002-9149(00)01042-0","article-title":"Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]).","volume":"86","author":"Diercks","year":"2000","journal-title":"Am J Cardiol"},{"key":"R13-9-20230601","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0031-6997(24)01359-0","article-title":"Signal transduction and signal modulation by cell adhesion receptors: The role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins.","volume":"50","author":"Aplin","year":"1998","journal-title":"Pharmacol Rev"},{"key":"R14-9-20230601","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/ki.1995.118","article-title":"Tyrosine kinase activity of the EGF receptor in murine metanephric organ culture.","volume":"47","author":"Pugh","year":"1995","journal-title":"Kidney Int"},{"key":"R15-9-20230601","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1046\/j.1523-1755.2003.00256.x","article-title":"EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.","volume":"64","author":"Torres","year":"2003","journal-title":"Kidney Int"},{"key":"R16-9-20230601","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1172\/JCI2071","article-title":"Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease.","volume":"101","author":"Richards","year":"1998","journal-title":"J Clin Invest"},{"key":"R17-9-20230601","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/ki.2014.84","article-title":"Deletion of ErbB4 accelerates polycystic kidney disease progression in cpk mice.","volume":"86","author":"Zeng","year":"2014","journal-title":"Kidney Int"},{"key":"R18-9-20230601","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0022-5347(01)64084-9","article-title":"Expression of transforming growth factor alpha and epidermal growth factor receptor in adult polycystic kidney disease.","volume":"159","author":"Lee","year":"1998","journal-title":"J Urol"},{"key":"R19-9-20230601","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0272-6386(12)70198-1","article-title":"Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcinoma.","volume":"19","author":"Klingel","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"R20-9-20230601","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0272-6386(12)80212-5","article-title":"Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: Possible evidence of heterogeneity in cystogenesis.","volume":"24","author":"Munemura","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"R21-9-20230601","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2353\/ajpath.2006.050342","article-title":"Defining a link with autosomal-dominant polycystic kidney disease in mice with congenitally low expression of Pkd1.","volume":"168","author":"Jiang","year":"2006","journal-title":"Am J Pathol"},{"key":"R22-9-20230601","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ki.1991.7","article-title":"Epidermal growth factor (EGF) expression in the congenital polycystic mouse kidney.","volume":"39","author":"Horikoshi","year":"1991","journal-title":"Kidney Int"},{"key":"R23-9-20230601","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","article-title":"Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys.","volume":"63","author":"Yamaguchi","year":"2003","journal-title":"Kidney Int"},{"key":"R24-9-20230601","doi-asserted-by":"crossref","first-page":"F982","DOI":"10.1152\/ajprenal.00677.2011","article-title":"Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways.","volume":"303","author":"Jansson","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"R25-9-20230601","doi-asserted-by":"crossref","first-page":"5639","DOI":"10.1091\/mbc.e05-05-0432","article-title":"Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells.","volume":"16","author":"Kiermayer","year":"2005","journal-title":"Mol Biol Cell"},{"key":"R26-9-20230601","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1111\/j.1742-4658.2005.04763.x","article-title":"Integrating signals between cAMP and the RAS\/RAF\/MEK\/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft f\u00fcr Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels.","volume":"272","author":"Dumaz","year":"2005","journal-title":"FEBS J"},{"key":"R27-9-20230601","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1053\/j.ajkd.2014.11.010","article-title":"Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function.","volume":"65","author":"Boertien","year":"2015","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201510000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:42:58Z","timestamp":1786369378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201510000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09941014","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}